Estimated Incidence of Hospitalizations Attributable to RSV Infection Among Adults in Ontario, Canada, Between 2013 and 2019.

Autor: Mitratza M; P95 Epidemiology and Pharmacovigilance, Leuven, Belgium., Elsobky M; Pfizer Canada Inc, Kirkland, Canada., Liang C; Pfizer Inc, 66 Hudson Blvd E, New York, NY, 10001, USA. caihua.liang@pfizer.com., Bruyndonckx R; P95 Epidemiology and Pharmacovigilance, Leuven, Belgium., Polkowska-Kramek A; P95 Epidemiology and Pharmacovigilance, Leuven, Belgium., Ewnetu WB; P95 Epidemiology and Pharmacovigilance, Leuven, Belgium., Peerawaranun P; P95 Epidemiology and Pharmacovigilance, Leuven, Belgium., Tran TMP; P95 Epidemiology and Pharmacovigilance, Leuven, Belgium., Nuttens C; Pfizer Inc, Paris, France., Grajales AG; Pfizer Canada Inc, Kirkland, Canada., Nzula S; Pfizer Canada Inc, Kirkland, Canada., Gessner BD; Pfizer Inc, 66 Hudson Blvd E, New York, NY, 10001, USA., Begier E; Pfizer Inc, Dublin, Ireland.
Jazyk: angličtina
Zdroj: Infectious diseases and therapy [Infect Dis Ther] 2024 Sep; Vol. 13 (9), pp. 1949-1962. Date of Electronic Publication: 2024 Jul 15.
DOI: 10.1007/s40121-024-01018-w
Abstrakt: Introduction: Adult respiratory syncytial virus (RSV) burden is underestimated due to non-specific symptoms, limited standard-of-care and delayed testing, reduced diagnostic test sensitivity-particularly when using single diagnostic specimen-when compared to children, and variable test sensitivity based on the upper airway specimen source. We estimated RSV-attributable hospitalization incidence among adults aged ≥ 18 years in Ontario, Canada, using a retrospective time-series model-based approach.
Methods: The Institute for Clinical Evaluative Sciences data repository provided weekly numbers of hospitalizations (from 2013 to 2019) for respiratory, cardiovascular, and cardiorespiratory disorders. The number of hospitalizations attributable to RSV was estimated using a quasi-Poisson regression model that considered probable overdispersion and was based on periodic and aperiodic time trends and viral activity. As proxies for viral activity, weekly counts of RSV and influenza hospitalizations in children under 2 years and adults aged 60 years and over, respectively, were employed. Models were stratified by age and risk group.
Results: In patients ≥ 60 years, RSV-attributable incidence rates were high for cardiorespiratory hospitalizations (range [mean] in 2013-2019: 186-246 [215] per 100,000 person-years, 3‒4% of all cardiorespiratory hospitalizations), and subgroups including respiratory hospitalizations (144-192 [167] per 100,000 person-years, 5‒7% of all respiratory hospitalizations) and cardiovascular hospitalizations (95-126 [110] per 100,000 person-years, 2‒3% of all cardiovascular hospitalizations). RSV-attributable cardiorespiratory hospitalization incidence increased with age, from 14-18 [17] hospitalizations per 100,000 person-years (18-49 years) to 317-411 [362] per 100,000 person-years (≥ 75 years).
Conclusions: Estimated RSV-attributable respiratory hospitalization incidence among people ≥ 60 years in Ontario, Canada, is comparable to other incidence estimates from high-income countries, including model-based and pooled prospective estimates. Recently introduced RSV vaccines could have a substantial public health impact.
(© 2024. Pfizer, Inc.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje